Research programme: cannabinoid receptor modulators - Sunovion Pharmaceuticals/IntelGenx

Drug Profile

Research programme: cannabinoid receptor modulators - Sunovion Pharmaceuticals/IntelGenx

Alternative Names: CAT 210; CAT 320; INT 0014/2008; Modulyn

Latest Information Update: 25 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cannasat Therapeutics
  • Developer Cynapsus Therapeutics; IntelGenx Corp.
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Anxiety disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 25 Oct 2016 Cynapsus Therapeutics has been acquired by Sunovion Pharmaceuticals
  • 31 Dec 2008 Preclinical trials in Schizophrenia in Canada (PO)
  • 07 Nov 2006 Preclinical trials in Chemotherapy induced nausea and vomiting in Canada (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top